31 articles for GG Chicchi
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
SAR exploration at the C-3 position of tetrahydro-ß-carboline sstr3 antagonists.
Merck Research Laboratories
A novel series of indazole-/indole-based glucagon receptor antagonists.
Merck Research Laboratories
Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists.
Merck Research Laboratories
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.
Merck Research Laboratories
Investigation of Cardiovascular Effects of Tetrahydro-ß-carboline sstr3 antagonists.
Merck Research Laboratories
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.
Merck Research Laboratories
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.
TBA
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.
TBA
Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.
Merck Research Laboratories
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
Merck Sharp & Dohme Research Laboratories
An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.
Merck
Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.
Merck Research Laboratories
Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.
Merck Research Laboratories
The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine.
Merck
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.
Merck Sharp & Dohme Research Laboratories
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
Merck Research Laboratories
Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
Merck Research Laboratories
NK1 antagonists based on seven membered lactam scaffolds.
Merck Sharp and Dohme Research Laboratories
1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.
Merck Sharp & Dohme Research Laboratories
Novel lactam NK1 antagonists with anti-emetic activity.
Merck Sharp & Dohme Research Laboratories
Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.
Merck Sharp & Dohme Research Laboratories
Spirocyclic NK(1) antagonists II: [4.5]-spiroethers.
Merck Sharp & Dohme Research Laboratories
4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists II.
Merck Sharp & Dohme Research Laboratories
4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists I.
Merck Sharp & Dohme Research Laboratories
2-Aryl indole NK(1) antagonists: optimisation of the amide substituent.
Merck Sharp & Dohme Research Laboratories
2-Aryl indole NK1 receptor antagonists: optimisation of the 2-aryl ring and the indole nitrogen substituent.
Merck Sharp and Dohme Research Laboratories
2-Aryl indole NK1 receptor antagonists: optimisation of indole substitution.
The Neuroscience Research Centre
Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
Merck Research Laboratories
4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity.
Merck Sharp and Dohme Research Laboratories